BR112022019932A2 - Composições para saúde metabólica - Google Patents

Composições para saúde metabólica

Info

Publication number
BR112022019932A2
BR112022019932A2 BR112022019932A BR112022019932A BR112022019932A2 BR 112022019932 A2 BR112022019932 A2 BR 112022019932A2 BR 112022019932 A BR112022019932 A BR 112022019932A BR 112022019932 A BR112022019932 A BR 112022019932A BR 112022019932 A2 BR112022019932 A2 BR 112022019932A2
Authority
BR
Brazil
Prior art keywords
compositions
metabolic health
same
metabolic
health
Prior art date
Application number
BR112022019932A
Other languages
English (en)
Inventor
L Stahl Buffy
Forssten Sofia
Hasselwander Oliver
Ann Hibberd Ashley
Max Jensen Henrik
M A Kane Helene
Kim Hye-Sook
Kumar Ritesh
Ouwehand Arthur
Tuulikki Rasinkangas Pia
E Rouviere Pierre
Wang Qiong
Original Assignee
Dupont Nutrition Biosci Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Nutrition Biosci Aps filed Critical Dupont Nutrition Biosci Aps
Publication of BR112022019932A2 publication Critical patent/BR112022019932A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES PARA SAÚDE METABÓLICA. A presente invenção refere-se a, entre outros, composições que compreendem uma ou mais cepas biologicamente puras de bactérias, assim como métodos para produzir e usar as mesmas para tratar e/ou prevenir um ou mais distúrbios relacionados à obesidade em um indivíduo em necessidade dos mesmos.
BR112022019932A 2020-04-03 2021-04-05 Composições para saúde metabólica BR112022019932A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063004617P 2020-04-03 2020-04-03
PCT/US2021/025730 WO2021203083A2 (en) 2020-04-02 2021-04-05 Compositions for metabolic health

Publications (1)

Publication Number Publication Date
BR112022019932A2 true BR112022019932A2 (pt) 2022-12-27

Family

ID=75769982

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019932A BR112022019932A2 (pt) 2020-04-03 2021-04-05 Composições para saúde metabólica

Country Status (9)

Country Link
US (1) US20230181653A1 (pt)
EP (1) EP4125441A2 (pt)
JP (1) JP2023542447A (pt)
KR (1) KR20220164002A (pt)
CN (1) CN116033835A (pt)
AU (1) AU2021246535A1 (pt)
BR (1) BR112022019932A2 (pt)
CA (1) CA3174352A1 (pt)
WO (2) WO2021203081A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092141A2 (en) 2021-11-22 2023-05-25 Dupont Nutrition Biosciences Aps Compositions for metabolic health
WO2023104887A1 (en) * 2021-12-09 2023-06-15 Société des Produits Nestlé S.A. Lactobacillus acidophilus to increase agmatine production by microbiota
WO2023201092A1 (en) * 2022-04-14 2023-10-19 Washington University Prevotella copri formulations and methods of use
CN115927109A (zh) * 2022-12-16 2023-04-07 暨南大学附属第一医院（广州华侨医院） 一种阿克曼菌后生元固体制剂的制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ES2440390B1 (es) * 2012-07-25 2014-11-13 Bioibérica, S.A. Composiciones para el tratamiento del sobrepeso y de la obesidad
WO2014196913A1 (en) * 2013-06-03 2014-12-11 Björck Inger Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
EP3297727A1 (en) * 2015-05-21 2018-03-28 Yeda Research and Development Co. Ltd Bacterial populations for promoting health
CA2998039A1 (en) * 2015-09-10 2017-03-16 Universite Catholique De Louvain Use of pasteurized akkermansia for treating metabolic disorders
AU2018309153A1 (en) * 2017-08-04 2020-03-19 Tarunmeet GUJRAL Roseburia hominis, Eubacterium eligens, and combinations thereof as biotherapeutics
JP7369690B2 (ja) * 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の細胞外小胞

Also Published As

Publication number Publication date
WO2021203081A1 (en) 2021-10-07
US20230181653A1 (en) 2023-06-15
KR20220164002A (ko) 2022-12-12
EP4125441A2 (en) 2023-02-08
CN116033835A (zh) 2023-04-28
WO2021203083A3 (en) 2022-02-24
AU2021246535A1 (en) 2022-10-27
WO2021203083A2 (en) 2021-10-07
CA3174352A1 (en) 2021-10-07
JP2023542447A (ja) 2023-10-10

Similar Documents

Publication Publication Date Title
BR112022019932A2 (pt) Composições para saúde metabólica
CO2022002413A2 (es) Composiciones y métodos para tratar la psoriasis y la dermatitis atópica usando prevotella histicola
BR112018015097A2 (pt) composição e reatores
GT201700246A (es) Métodos y kits para tratar la depresión
AR106800A1 (es) Composiciones que comprenden cepas bacterianas
BR112021025676A2 (pt) Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella
BR112017005044A2 (pt) composições compreendendo uma ou mais cepas microbianas, célula vegetal tendo um revestimento, método para produzir um consórcio microbiano, consórcio microbiano, método para melhorar a saúde, o crescimento ou a produtividade de uma planta
CL2021002602A1 (es) Células microbianas, métodos para producir las mismas, y usos de las mismas (divisional de la solicitud no. 201902135)
BR112018008312A2 (pt) cepas, composição, e, kit
BR112015012789A2 (pt) composição que compreende um agente de controle biológico e um inseticida
BR112014008666A8 (pt) acelerando recuperação de músculo após a atrofia muscular ter induzido imobilização
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
CO2020004034A2 (es) Métodos para el tratamiento de distrofia muscular
CO2020012954A2 (es) Siloxanos biocompatibles para formulación de microorganismos
BR112017015876A2 (pt) microrganismos geneticamente modificados que apresentam tolerância melhorada à l-serina
BR112022020780A2 (pt) Composições de trem e usos das mesmas
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
CO2023000114A2 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae
CO2022014499A2 (es) Moduladores de nlrp3
CO2023004540A2 (es) Formas farmacéuticas sólidas de bacterias
CO2021014024A2 (es) Métodos para tratar la distrofia muscular con casimersin
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
BR112022010411A2 (pt) Composições bacterianas projetadas e usos das mesmas
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
BR112022000314A2 (pt) Redução da transmissão da malária